These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 7910219)

  • 21. p53, p21, Rb and mdm2 oncoproteins. Expression in normal placenta, partial and complete mole, and choriocarcinoma.
    Fulop V; Mok SC; Genest DR; Gati I; Doszpod J; Berkowitz RS
    J Reprod Med; 1998 Feb; 43(2):119-27. PubMed ID: 9513873
    [TBL] [Abstract][Full Text] [Related]  

  • 22. p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor.
    Poller DN; Hutchings CE; Galea M; Bell JA; Nicholson RA; Elston CW; Blamey RW; Ellis IO
    Br J Cancer; 1992 Sep; 66(3):583-8. PubMed ID: 1355662
    [TBL] [Abstract][Full Text] [Related]  

  • 23. P53 in breast carcinomas: association between presence of mutation and immunohistochemical expression using a semiquantitative approach.
    Schmitt FC; Soares R; Cirnes L; Seruca R
    Pathol Res Pract; 1998; 194(12):815-9. PubMed ID: 9894246
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High prevalence of HER-2/neu and p53 overexpression in inflammatory breast cancer.
    Sawaki M; Ito Y; Akiyama F; Tokudome N; Horii R; Mizunuma N; Takahashi S; Horikoshi N; Imai T; Nakao A; Kasumi F; Sakamoto G; Hatake K
    Breast Cancer; 2006; 13(2):172-8. PubMed ID: 16755113
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma.
    Izquierdo MA; van der Zee AG; Vermorken JB; van der Valk P; Beliën JA; Giaccone G; Scheffer GL; Flens MJ; Pinedo HM; Kenemans P
    J Natl Cancer Inst; 1995 Aug; 87(16):1230-7. PubMed ID: 7563169
    [TBL] [Abstract][Full Text] [Related]  

  • 26. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer.
    Barbareschi M; Leonardi E; Mauri FA; Serio G; Dalla Palma P
    Am J Clin Pathol; 1992 Oct; 98(4):408-18. PubMed ID: 1357956
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer.
    Lukes AS; Kohler MF; Pieper CF; Kerns BJ; Bentley R; Rodriguez GC; Soper JT; Clarke-Pearson DL; Bast RC; Berchuck A
    Cancer; 1994 May; 73(9):2380-5. PubMed ID: 7909491
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression and mutation of the tumor suppressor gene p53 in AIDS-associated Kaposi's sarcoma.
    Li JJ; Huang YQ; Cockerell CJ; Zhang WG; Nicolaides A; Friedman-Kien AE
    Am J Dermatopathol; 1997 Aug; 19(4):373-8. PubMed ID: 9261472
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship between p53 gene mutations and multidrug resistance (mdr1) gene expression in myelodysplastic syndromes.
    Preudhomme C; Lepelley P; Vachee A; Soenen V; Quesnel B; Cosson A; Fenaux P
    Leukemia; 1993 Nov; 7(11):1888-90. PubMed ID: 7901457
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular abnormalities of p53, MDM2, and H-ras in synovial sarcoma.
    Oda Y; Sakamoto A; Satio T; Kawauchi S; Iwamoto Y; Tsuneyoshi M
    Mod Pathol; 2000 Sep; 13(9):994-1004. PubMed ID: 11007040
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.
    Press MF; Pike MC; Chazin VR; Hung G; Udove JA; Markowicz M; Danyluk J; Godolphin W; Sliwkowski M; Akita R
    Cancer Res; 1993 Oct; 53(20):4960-70. PubMed ID: 8104689
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlations among p53, Her-2/neu, and ras overexpression and aneuploidy by multiparameter flow cytometry in human breast cancer: evidence for a common phenotypic evolutionary pattern in infiltrating ductal carcinomas.
    Smith CA; Pollice AA; Gu LP; Brown KA; Singh SG; Janocko LE; Johnson R; Julian T; Hyams D; Wolmark N; Sweeney L; Silverman JF; Shackney SE
    Clin Cancer Res; 2000 Jan; 6(1):112-26. PubMed ID: 10656439
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of c-erbB-2 protein and epidermal growth receptor in endometrial carcinomas. Correlation with clinicopathologic and sex steroid receptor status.
    Wang D; Konishi I; Koshiyama M; Mandai M; Nanbu Y; Ishikawa Y; Mori T; Fujii S
    Cancer; 1993 Nov; 72(9):2628-37. PubMed ID: 8104681
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunohistochemical detection of p53 overexpression in formalin-fixed, paraffin-embedded sections of endometrial carcinoma.
    Iwai K; Hachisuga T; Iwasaka T; Sugimori H
    J Obstet Gynaecol (Tokyo 1995); 1995 Dec; 21(6):593-600. PubMed ID: 8640471
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunohistochemical expression of p53 and c-erbB2 proteins in breast cancer in Egypt.
    el-A Helal T; Khalifa A; Kamel AS
    Anticancer Res; 2000; 20(3B):2145-50. PubMed ID: 10928168
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oncoprotein (c-myc, c-erbB1, c-erbB2, c-fos) and suppressor gene product (p53) expression in squamous cell carcinomas of the lung. Clinical and biological correlations.
    Volm M; Efferth T; Mattern J
    Anticancer Res; 1992; 12(1):11-20. PubMed ID: 1348920
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma.
    Kuhn EJ; Kurnot RA; Sesterhenn IA; Chang EH; Moul JW
    J Urol; 1993 Nov; 150(5 Pt 1):1427-33. PubMed ID: 8105108
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunohistochemical detection of p53 protein expression in mammary carcinoma: a study of 80 cases.
    Fernando SS; Wu X; McKenzie P; Johnson SJ
    Pathology; 1995 Oct; 27(4):365-9. PubMed ID: 8771158
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proliferative activity in breast carcinoma evaluated by BrdU and PCNA. Correlation with expression of p53, c-erbB-2, estrogen receptor and P-glycoprotein.
    Moriki T; Takahashi T; Tanioka F; Yamane T; Hara H
    Pathol Res Pract; 1995 Nov; 191(11):1122-32. PubMed ID: 8822114
    [TBL] [Abstract][Full Text] [Related]  

  • 40. No evidence of significant activity of the multidrug resistance gene product in primary human breast cancer.
    Hegewisch-Becker S; Staib F; Löning T; Pichlmeier U; Kröger N; Reymann A; Hossfeld DK
    Ann Oncol; 1998 Jan; 9(1):85-93. PubMed ID: 9541688
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.